<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">31825</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Editorial article</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Передовая статья</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Intercurrent and autoimmune processes in type 1 diabetes mellitus</article-title><trans-title-group xml:lang="ru"><trans-title>Интеркуррентные аутоиммунные процессы при сахарном диабете 1-го типа</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Derevyanko</surname><given-names>O S</given-names></name><name xml:lang="ru"><surname>Деревянко</surname><given-names>О С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nikonova</surname><given-names>T V</given-names></name><name xml:lang="ru"><surname>Никонова</surname><given-names>Т В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Smirnova</surname><given-names>O M</given-names></name><name xml:lang="ru"><surname>Смирнова</surname><given-names>О М</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dedov</surname><given-names>I I</given-names></name><name xml:lang="ru"><surname>Дедов</surname><given-names>И И</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">«Эндокринологический научный центр» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2015-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2015</year></pub-date><volume>87</volume><issue>10</issue><issue-title xml:lang="en">VOL 87, NO10 (2015)</issue-title><issue-title xml:lang="ru">ТОМ 87, №10 (2015)</issue-title><fpage>50</fpage><lpage>53</lpage><history><date date-type="received" iso-8601-date="2020-04-10"><day>10</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2015, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2015, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/31825">https://ter-arkhiv.ru/0040-3660/article/view/31825</self-uri><abstract xml:lang="en"><p>Aim. To estimate the prevalence of autoantibodies pathognomonic for autoimmune diseases of connective tissue and liver in patients with type 1 diabetes mellitus (DM1) and to study their clinical features in patients positive for these indicators. Subjects and methods. A total of 84 patients (39 men and 45 women) with DM1 divided into 2 groups were examined. Biochemical, immunological, and instrumental examinations were performed. Results. There was a high prevalence of markers of autoimmune diseases of connective tissue and liver in patients with DM1 and that of autoantibodies in those without its clinical symptoms or signs according to instrumental findings. Conclusion. The findings may suggest that patients with DM1 have a higher risk of concomitant autoimmune diseases with a probability of their asymptomatic course.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Оценка распространенности аутоантител, характерных для аутоиммунных заболеваний соединительной ткани и печени, у больных сахарным диабетом 1-го типа (СД-1), изучение особенностей клинической картины у пациентов, положительных по данным параметрам. Материалы и методы. Обследовали 84 пациента (39 мужчин, 45 женщин) с СД-1, которых разделили на 2 группы. Провели биохимическое, иммунологическое и инструментальное обследование. Результаты. Установлена высокая распространенность маркеров аутоиммунных заболеваний соединительной ткани и печени у пациентов с СД-1, а также антител у пациентов без клинической симптоматики, признаков поражения по данным инструментальных исследований. Заключение. На основе полученных данных можно предположить, что пациенты с СД-1 имеют более высокий риск возникновения сопутствующих аутоиммунных заболеваний с возможностью их бессимптомного течения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>type 1 diabetes mellitus</kwd><kwd>autoimmune hepatitis</kwd><kwd>autoimmunity</kwd><kwd>antinuclear antibodies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сахарный диабет 1-го типа</kwd><kwd>аутоиммунный гепатит</kwd><kwd>аутоиммунитет</kwd><kwd>антинуклеарные антитела</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wägner AM, Santana Á, Hernández M, Wiebe JC, Nóvoa J, Maurici D. Predictors of associated autoimmune diseases (AAID) in families with type 1 diabetes (T1D). Results from the Type 1 Diabetes Genetics Consortium (T1DGC) Diabetes. Metab Res Rev. 2011;27(5):493-498. doi:10.1002/dmrr.1189.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Barker JM, Yu J, Yu L, Wang J, Miao D, Bao F. Autoantibody «subspecificity» in type 1 diabetes: Risk for organ-specific autoimmunity clusters in distinct groups. Diabetes Care. 2005;28(4): 850-855.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Triolo TM, Armstrong TK, McFann K, Yu L, Rewers MJ, Klingensmith GJ, Eisenbarth GS, Barker JM. Additional Autoimmune Disease Found in 33% of Patients at Type 1 Diabetes Onset. Diabetes Care. 2011;34(5):1211-1213.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tsirogianni A, Pipi E, Soufleros K. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus. Autoimmun Rev. 2009;8(8): 687-915.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Damoiseaux J, Agmon-Levin N, Blerk MV, Chopyak V, Eriksson C, Heijnen I, Herold M, Høgåsen K, Musset L, Radice A, de Sousa MJR, Viander M, Shoenfeld Y. From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries. Clin Exp Rheumatol. 2014;32(4):539-646. Epub 2014 Jun 30.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>American College of rheumatology (ACR). Position Statement Methodology of Testing for Antinuclear Antibodies. 2009.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Czaja Albert J, Freese Deborah K. Diagnosis and Treatment of Autoimmune Hepatitis. AASLD Practice Guidelines; 2012.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Navaneethan U, Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease. Inflamm Bowel Dis. 2010;16(9):1598-1619. doi:10.1002/ibd.21219.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine. 2006;85(2):95-104.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez А, Rube ́n D. Mantilla, Anaya JM. Introducing Polyautoimmunity: Secondary Autoimmune Diseases No Longer Exist. Autoimmune Dis. 2012;Article ID 254319. 9 pages. doi:10.1155/2012/254319.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev. 2011;91:79-118.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: A clinical review. Neth J Med. 2009;67(11):376-387.</mixed-citation></ref></ref-list></back></article>
